---
title: "Spyre Therapeutics, Inc. (SYRE.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/SYRE.US.md"
symbol: "SYRE.US"
name: "Spyre Therapeutics, Inc."
industry: "Biotechnology"
---

# Spyre Therapeutics, Inc. (SYRE.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.spyre.com](https://www.spyre.com) |

## Company Profile

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage desi...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -27.42 | 519/603 | - | - | - |
| PB | 6.20 | 322/603 | 7.94 | 3.29 | 2.83 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-23T05:00:00.000Z

Total Analysts: **17**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 16 | 94% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 43.45 |
| Highest Target | 70.00 |
| Lowest Target | 40.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/SYRE.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/SYRE.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/SYRE.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.